Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2012 Results
Date:5/8/2012

24.  The tasimelteon Non-24 program continues to advance towards the goal of a projected mid-2013 NDA filing with the FDA.  Vanda is in continuing discussions with the FDA to confirm the path and requirements for this regulatory submission.  Vanda expects to complete the two Phase III efficacy studies, SET and RESET, by the end of 2012.

The tasimelteon MAGELLAN efficacy study for MDD is ongoing and Vanda expects to report top-line results in the first half of 2013.  This Phase IIb/III study in MDD is expected to enroll 500 patients across approximately 40 sites in the U.S.

On April 16, 2012, Vanda announced that it had obtained exclusive world-wide rights from Eli Lilly and Company to develop and commercialize VLY-686, a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.  In 2012, Vanda intends to initiate and complete the technology transfer activities and further examine the clinical and commercial profile of VLY-686.  This strategic evaluation will further inform potential indications for an early clinical development program.  VLY-686 is a Phase II ready program.

First quarter 2012 sales of Fanapt® were reported by Novartis to be $15.4 million.  Fanapt® prescriptions, as reported by IMS, reached 35,000 for the first quarter of 2012.  This represents a 39% increase over first quarter 2011 prescriptions.

The review of Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets in the European Union is ongoing.  The European Medicines Agency (EMA) has provided its standard 120-day list of questions and has granted Vanda a 3-month extension, through mid-May 2012.  Vanda expects to respond to the EMA questions by such time.  Regulatory filings for market approval of Fanapt® by Vanda's commercial partners are under review in Israel, Mexico and Argentina. 

2012 FINANCIAL GUIDANCE

  • General
    '/>"/>

  • SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
    2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
    3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
    4. Vanda Presents Phase III Iloperidone Efficacy Data
    5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
    6. Vanda Pharmaceuticals Provides Update on Iloperidone
    7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
    8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
    9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
    10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
    11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
    (Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
    Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
    (Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
    (Date:7/9/2014)... Infectious Diseases (NIAID), part of the National Institutes ... of CRS3123, an investigational oral antibiotic intended to ... ) infection. CRS3123 (previously known as REP3123) is ... while sparing normal intestinal bacteria. , The Phase ... men and women ages 18 to 45 in ...
    (Date:7/9/2014)... A retrospective study conducted by researchers at Tufts ... among adults with intellectual and developmental disabilities, the likelihood ... receiving dental care increased. The findings, published in the ... may help improve interventions designed to address the oral ... researchers reviewed the dental records of 107 patients at ...
    (Date:7/9/2014)... older age with kidney and heart disease have raised ... older adults. However, in the first study to look ... of Medicine at the University of Pennsylvania report that ... life expectancy and cardiovascular health as very healthy older ... of the ever increasing organ transplant waitlists, the authors ...
    (Date:7/9/2014)... published in the scientific journal Nature Neuroscience ... at Universit Laval, reveals that it is possible to ... rekindling pain so that it can subsequently be erased. ... chronic pain. , The researchers from the Faculty of ... mentale de Qubec (IUSMQ) were inspired by previous work ...
    Breaking Medicine News(10 mins):Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:Discovery of a new means to erase pain 2
    ... a challenge for patients in the U.S. health care ... an updated paper released today. Racial and Ethnic ... a policy paper that was originally released in 2003, ... racial and ethnic minority patients and their white counterparts. ...
    ... bioGUNE and led by Dr. Aitor Hierro, have opened ... of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), ... of the National Academy of Sciences of the ... possibility of research in humans to detect this pathology ...
    ... 2010 The Marilyn B. Gula Mountains of Hope ... a $50,000 donation to the Phoenix-based Translational Genomics Research ... of $300,000. In addition, the Mountains of Hope ... Hospitals (UH) Ireland Cancer Center, bringing the total donated ...
    ... during surgery for less complicated congenital heart defects ... neurocognitive abilities, such as intelligence, memory, motor skills ... Hospital of Philadelphia, in a study in the ... neuropsychological effects after surgery for acyanotic heart defects. ...
    ... School of Medicine have discovered that a kind of ... but not found in humans provokes a strong immune ... chronic inflammation is a major issue. This non-human ... drugs, and may be limiting or undermining their therapeutic ...
    ... , FRIDAY, July 23 (HealthDay News) -- As the nation ... Disabilities Act on Monday, a new survey finds that the ... of life for people with disabilities. Many social and ... disabilities and those without, according to a survey conducted by ...
    Cached Medicine News:Health News:Disparities remain a challenge in health care says American College of Physicians 2Health News:New approach which can help to predict neurodegenerative diseases 2Health News:New approach which can help to predict neurodegenerative diseases 3Health News:The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen 2Health News:Heart bypass for uncomplicated heart surgery does not reduce neurocognitive function in children 2Health News:Non-human sugar in biotech drugs causes inflammation 2Health News:Non-human sugar in biotech drugs causes inflammation 3Health News:Americans With Disabilities Act Reaches 20th Anniversary 2Health News:Americans With Disabilities Act Reaches 20th Anniversary 3Health News:Americans With Disabilities Act Reaches 20th Anniversary 4
    24-Well Slot Blot...
    ... Disposable, clear, APET plastic tray. Ideal for ... those trays used for multipurposes. Pour spouts ... A marker or label may be used ... trays on rockers or shakers for staining ...
    ... with vacuum stage, porous vacuum plate, reservoir seal ... The Model 785 vacuum blotter quickly and ... gel onto a nylon membrane. Because it generally ... acid samples can be separated on a gel, ...
    ... vacuum stage, porous vacuum plate, reservoir seal O-ring, ... The Model 785 vacuum blotter quickly and efficiently ... onto a nylon membrane. Because it generally requires ... samples can be separated on a gel, transferred ...
    Medicine Products: